COV and CVALF Related Headlines
Go Back- Covalon Reports 2026 Second Quarter Results
- Covalon Announces Conference Call to Discuss Second Quarter Fiscal 2026 Results
- Covalon Technologies Reports Significant Milestones Spanning Vascular Access, Infection Prevention, and Wound Care
- Covalon to Showcase Clinical Innovation and Infection Prevention Leadership at Infusion Nurses Society 2026 Annual Meeting
- Covalon Announces Grant of Deferred Share Units
- Covalon Announces Voting Results from Fiscal 2025 Annual General and Special Meeting of Shareholders
- Covalon To Hold Annual Meeting of Shareholders on Wednesday, March 25, 2026
- Covalon Reports on 2026 First Quarter Results and Recent Achievements and Highlights
- Covalon Honoured to Partner with the Association for Vascular Access and Global Expert Dr. Nancy Moureau to Tackle Critical IV Therapy Complications
- Covalon Announces Conference Call to Discuss First Quarter Fiscal 2026 Results
- Covalon Reports Highest Revenue Quarter of Fiscal Year 2025, Delivers Third Consecutive Year of Revenue Growth
- Covalon Announces Conference Call to Discuss Fourth Quarter and Year End Fiscal 2025 Financial Results
- Covalon Technologies Ltd. Announces Payment of First Ever Dividend, Marking a Milestone in Financial Strength
- Covalon Declares First Ever Special Cash Dividend
- Covalon to Participate in the Planet MicroCap Showcase: TORONTO on October 22, 2025
- Empowering Nurses with Innovation: Covalon Showcases Patient Safety Solutions to Tackle Preventable Complications at ANCC National Magnet & Pathway Conference
- Covalon Presents Evidence-Backed Innovations Making a Difference for Critically Ill Children at APHON
- Covalon Announces Departure of Executive Chair and the Appointment of its Largest Shareholder as New Chair
- Evidence-Driven Outcomes and Clinical Innovation Highlight Covalon’s Presence at the Association for Vascular Access 2025 Annual Meeting
- Covalon Announces Publication of Impactful VALGuard® Line Guard Clinical Study Demonstrating Significant Reduction in Central Line-Associated Blood Stream Infections (CLABSIs)
- Covalon Reports Strong Sequential Quarter on Quarter and Trailing Twelve Months Performance
- Covalon Technologies Ltd. Achieves DTC Eligibility in the United States
- Covalon Announces Conference Call to Discuss Third Quarter Fiscal 2025 Financial Results
COV and CVALF Related Press Releases
Go Back- Covalon Reports 2026 Second Quarter Results
- Covalon Announces Conference Call to Discuss Second Quarter Fiscal 2026 Results
- Covalon Technologies Reports Significant Milestones Spanning Vascular Access, Infection Prevention, and Wound Care
- Covalon to Showcase Clinical Innovation and Infection Prevention Leadership at Infusion Nurses Society 2026 Annual Meeting
- Covalon Announces Grant of Deferred Share Units
- Covalon Announces Voting Results from Fiscal 2025 Annual General and Special Meeting of Shareholders
- Covalon To Hold Annual Meeting of Shareholders on Wednesday, March 25, 2026
- Covalon Reports on 2026 First Quarter Results and Recent Achievements and Highlights
- Covalon Honoured to Partner with the Association for Vascular Access and Global Expert Dr. Nancy Moureau to Tackle Critical IV Therapy Complications
- Covalon Announces Conference Call to Discuss First Quarter Fiscal 2026 Results
- Covalon Reports Highest Revenue Quarter of Fiscal Year 2025, Delivers Third Consecutive Year of Revenue Growth
- Covalon Announces Conference Call to Discuss Fourth Quarter and Year End Fiscal 2025 Financial Results
- Covalon Technologies Ltd. Announces Payment of First Ever Dividend, Marking a Milestone in Financial Strength
- Covalon Declares First Ever Special Cash Dividend
- Covalon to Participate in the Planet MicroCap Showcase: TORONTO on October 22, 2025
- Empowering Nurses with Innovation: Covalon Showcases Patient Safety Solutions to Tackle Preventable Complications at ANCC National Magnet & Pathway Conference
- Covalon Presents Evidence-Backed Innovations Making a Difference for Critically Ill Children at APHON
- Covalon Announces Departure of Executive Chair and the Appointment of its Largest Shareholder as New Chair
- Evidence-Driven Outcomes and Clinical Innovation Highlight Covalon’s Presence at the Association for Vascular Access 2025 Annual Meeting
- Covalon Announces Publication of Impactful VALGuard® Line Guard Clinical Study Demonstrating Significant Reduction in Central Line-Associated Blood Stream Infections (CLABSIs)
- Covalon Reports Strong Sequential Quarter on Quarter and Trailing Twelve Months Performance
- Covalon Technologies Ltd. Achieves DTC Eligibility in the United States
- Covalon Announces Conference Call to Discuss Third Quarter Fiscal 2025 Financial Results
